LYELL IMMUNOPHARMA IN

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

07 ноя 2024 16:05:03 Источник Nasdaq GlobeNewswire

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

05 ноя 2024 09:30:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Completes Acquisition of ImmPACT Bio

31 окт 2024 16:00:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies

24 окт 2024 16:00:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance Abstracts for Presentation at 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting

04 окт 2024 09:00:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in Goldman Sachs Cell Therapy Day

24 сен 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in September Investor Conferences

28 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2024

07 авг 2024 16:05:01 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology

26 июн 2024 07:00:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference

03 июн 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Health Care Conference

07 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

06 май 2024 08:00:01 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting

05 мар 2024 16:30:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

28 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces Participation in March Investor Conferences

26 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

09 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

07 ноя 2023 16:05:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

31 окт 2023 09:00:00 Источник Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

27 сен 2023 09:00:00 Источник Nasdaq GlobeNewswire